The Power of GenAI in Life Sciences - Elizabeth Smalley ArisGlobal

Life Science Success

This week on Life Science Success, we are thrilled to welcome back Elizabeth Smalley as our guest. Elizabeth is the VP, Product Management, Data & Analytics at ArisGlobal, where she plays a pivotal role in steering the company’s strategic initiatives in the realms of artificial intelligence and machine learning within the life sciences sector. With an impressive background that bridges technology and life sciences, Elizabeth has been instrumental in the formation and launch of the GenAI Council, an innovative effort aimed at harnessing generative AI to revolutionize research and development in life sciences.

• Introduction of Guests and Focus: Don, a consultant in life sciences, introduces Elizabeth Smalley, VP of Product Management, Data, and Analytics at ArisGlobal. The discussion emphasizes the transformative power of generative AI (GenAI) in the life sciences sector, with a particular focus on Elizabeth's leadership in strategic AI initiatives at ArisGlobal.

• Elizabeth Smalley's Background and Journey: Elizabeth recounts her diverse experience in product management across e-commerce, manufacturing, and healthtech. Her story highlights the central role of AI in her career, including significant achievements in developing AI-driven clinical solutions at Teladoc Health and her progression to leading ArisGlobal's data, analytics, and AI strategies.

• ArisGlobal's Innovations and Role: The conversation explores ArisGlobal's impact on life sciences, especially its innovative use of AI in pharmacovigilance and regulatory processes. Elizabeth points out ArisGlobal's pioneering introduction of AI into case processing workflows and its leadership in adopting generative AI, aiming to enhance efficiency and patient safety in the sector.

• Generative AI: Challenges and Opportunities: Elizabeth discusses the economic potential of generative AI in life sciences, acknowledging regulatory challenges and the necessity of industry-wide collaboration to navigate these. She emphasizes the importance of creating a responsible AI adoption playbook, addressing transparency, and fostering innovation within a regulatory framework.

• Vision for the Future: The interview concludes with a forward-looking view on how generative AI could revolutionize patient care, streamline drug development, and optimize regulatory compliance. Elizabeth advocates for a collaborative approach to leverage AI responsibly, aiming to improve health outcomes, enhance operational efficiencies, and ensure patient safety in the evolving landscape of life sciences.